Q3 EPS Estimates for Exact Sciences Boosted by Analyst

Exact Sciences Co. (NASDAQ:EXAS - Free Report) - Equities research analysts at Leerink Partnrs upped their Q3 2025 EPS estimates for Exact Sciences in a research report issued on Monday, April 21st. Leerink Partnrs analyst P. Souda now expects that the medical research company will post earnings per share of $0.17 for the quarter, up from their previous forecast of $0.12. The consensus estimate for Exact Sciences' current full-year earnings is ($0.58) per share.

Several other equities analysts also recently weighed in on the stock. Guggenheim restated a "buy" rating and set a $60.00 target price on shares of Exact Sciences in a report on Friday, April 11th. Benchmark reiterated a "buy" rating and set a $65.00 price target on shares of Exact Sciences in a report on Monday, January 13th. Mizuho started coverage on shares of Exact Sciences in a report on Thursday, April 10th. They set an "outperform" rating and a $60.00 price target for the company. Royal Bank of Canada started coverage on shares of Exact Sciences in a report on Thursday, March 13th. They set a "sector perform" rating and a $52.00 price target for the company. Finally, William Blair reiterated an "outperform" rating on shares of Exact Sciences in a report on Thursday, February 20th. Two research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $69.25.

Exact Sciences Price Performance

NASDAQ:EXAS traded down $0.14 during mid-day trading on Tuesday, hitting $45.46. 1,093,684 shares of the company's stock traded hands, compared to its average volume of 2,608,749. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15. The firm's 50 day simple moving average is $45.34 and its 200 day simple moving average is $54.01. Exact Sciences has a 1 year low of $39.97 and a 1 year high of $72.83. The company has a market cap of $8.44 billion, a PE ratio of -8.16 and a beta of 1.14.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The firm had revenue of $713.42 million during the quarter, compared to analysts' expectations of $701.45 million.

Institutional Trading of Exact Sciences

Several large investors have recently modified their holdings of EXAS. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Exact Sciences during the first quarter valued at about $34,000. Asset Planning Inc acquired a new stake in shares of Exact Sciences during the fourth quarter valued at about $40,000. Modus Advisors LLC acquired a new stake in shares of Exact Sciences during the fourth quarter valued at about $43,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Exact Sciences during the fourth quarter valued at about $45,000. Finally, AlphaQuest LLC grew its stake in Exact Sciences by 22,825.0% in the fourth quarter. AlphaQuest LLC now owns 917 shares of the medical research company's stock worth $52,000 after purchasing an additional 913 shares in the last quarter. 88.82% of the stock is currently owned by institutional investors and hedge funds.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.